Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Abbisko Cayman Limited ( (HK:2256) ) has shared an update.
Abbisko Therapeutics has begun dosing the first patient in a Phase II trial of its FGFR4 inhibitor irpagratinib in combination with toripalimab and a bevacizumab biosimilar as a first-line treatment for advanced or unresectable hepatocellular carcinoma. The study specifically targets patients whose tumors overexpress FGF19, a group shown to respond less well to current targeted-immunotherapy regimens.
Previous Phase II data presented at ESMO GI 2025 showed that irpagratinib combined with atezolizumab produced an objective response rate above 50% and median progression-free survival exceeding seven months in FGF19-overexpressing HCC, with a manageable safety profile. Building on this, the new triplet regimen aims to enhance antitumor activity via a complementary mechanism and could strengthen Abbisko’s position in precision oncology if the results support improved outcomes in this hard-to-treat population.
The most recent analyst rating on (HK:2256) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited, through its subsidiary Abbisko Therapeutics, operates in the biopharmaceutical industry with a focus on developing targeted small-molecule therapies for oncology. The company’s pipeline includes irpagratinib, a highly selective oral FGFR4 inhibitor aimed at treating hepatocellular carcinoma patients with FGF19 overexpression, a subgroup with significant unmet medical needs.
Average Trading Volume: 1,674,084
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.24B
For an in-depth examination of 2256 stock, go to TipRanks’ Overview page.